ImmuPharma plc (LON:IMM – Get Free Report) was down 13.9% during mid-day trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 5.08 ($0.06). Approximately 54,879,313 shares traded hands during mid-day trading, an increase of 118% from the average daily volume of 25,154,164 shares. The stock had previously closed at GBX 5.90 ($0.07).
ImmuPharma Trading Down 20.1 %
The firm’s fifty day moving average price is GBX 1.92 and its 200-day moving average price is GBX 1.78. The company has a market cap of £19.64 million, a P/E ratio of -471.50 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- 5 discounted opportunities for dividend growth investors
- 3 Trucking Stocks Leading the Way in Market Momentum
- What is a Dividend King?
- 3 Stocks to Gain From Trump’s Family Caregiver Tax Credits
- The 3 Best Retail Stocks to Shop for in August
- Charging Forward: 2 US Battery Stocks to Electrify Your Portfolio
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
